KRYS
vs
S&P 500
KRYS
S&P 500
Over the past 12 months, KRYS has underperformed S&P 500, delivering a return of -24% compared to the S&P 500's 9% growth.
Stocks Performance
KRYS vs S&P 500
Performance Gap
KRYS vs S&P 500
Performance By Year
KRYS vs S&P 500
Krystal Biotech Inc
Glance View
Krystal Biotech Inc. ventures into the complex but promising world of gene therapy, a field that carries the potential to transform how genetic diseases are treated. Founded in 2016, this Pennsylvania-based company focuses on developing and commercializing redosable gene therapies for patients suffering from debilitating skin diseases. Their flagship program, centered on a product called B-VEC, targets dystrophic epidermolysis bullosa (DEB), a rare and severe genetic skin disorder that causes fragile skin prone to blistering. Krystal Biotech leverages a proprietary gene delivery platform, based on herpes simplex virus (HSV-1), to transport corrective copies of genes directly to the affected skin cells, aiming to accelerate healing and dramatically improve patients’ quality of life. In terms of its business model, Krystal Biotech generates revenue primarily by bringing these transformative therapies to market, tapping into unmet medical needs that traditionally lacked effective solutions. By focusing on rare diseases, which often face less competitive pressure, Krystal positions itself in a niche but critical segment of the healthcare market. The company undertakes extensive clinical trials and regulatory processes to ensure its therapies demonstrate safety and efficacy before securing approvals. Additionally, Krystal actively engages with the healthcare ecosystem, including insurers and providers, to facilitate patient access and reimbursement. This strategic pathway not only enables the company to generate revenue but also aligns with its mission of transforming lives through innovative science.
You don't have any saved screeners yet